TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20179692

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (manometric‐assisted pelvic relaxation and simulated defecation training)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard therapy (diet, exercise, laxatives)
Number of subjects: 26
Study: 17328907

Group type: EXPERIMENTAL
Intervention: Preparatory information with accurate description and real props
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Preparatory information with accurate description and toy props
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Preparatory information with accurate description and verbal props
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Preparatory information with misleading verbal and misleading props
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Preparatory information with accurate description and misleading props
Number of subjects: 6

Group type: COMPARATOR
Intervention: Attentional control condition
Number of subjects: 6
Study: 15766369

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing
Number of subjects: 44

Group type: COMPARATOR
Intervention: No periodontal treatment (Control)
Number of subjects: 44
Study: 11482162

Group type: EXPERIMENTAL
Intervention: 5 gm of ginger powder with fatty meal
Number of subjects: 30

Group type: COMPARATOR
Intervention: 50 gm of fat
Number of subjects: 30
Study: 10193351

Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase, 250,000 IU daily for three days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control saline flushes for three days
Number of subjects: 24
Study: 7915149

Group type: EXPERIMENTAL
Intervention: Intermediate purity factor VIII or factor IX concentrates, or cryoprecipitate
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Cryoprecipitate
Number of subjects: 525
Study: 3393781

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (oral administration)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cefotaxime (intravenous administration)
Number of subjects: 70
Study: 29478257

Group type: EXPERIMENTAL
Intervention: Bortezomib plus dexamethasone (BD)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Thalidomide plus dexamethasone (TD)
Number of subjects: 44
Study: 28139479

Group type: EXPERIMENTAL
Intervention: Chitosan modified glass ionomer cement (10% v/v)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-cetrimide modified glass ionomer cement (2.5/2.5% w/w)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional glass ionomer cement
Number of subjects: 50
Study: 26444334

Group type: EXPERIMENTAL
Intervention: Intravenous injection (i.v.) of PHC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular injection (i.m.) of PHC
Number of subjects: 0
Study: 24073527

Group type: EXPERIMENTAL
Intervention: Pro‐Relief in‐office desensitizing fluoride‐free paste containing 8% arginine and calcium carbonate (Test Paste group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoride‐free prophylaxis paste (Control Paste group)
Number of subjects: 50
Study: 21820860

Group type: EXPERIMENTAL
Intervention: 1.0mg fluoride tablet (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5mg fluoride tablet (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 0
Study: 18927594

Group type: EXPERIMENTAL
Intervention: Aspheric IOL (Tecnis ZA9003)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Spherical IOL (AcrySof SA60AT)
Number of subjects: 48
Study: 16620590

Group type: EXPERIMENTAL
Intervention: Intramuscular revaccination (10 microg per dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intradermal revaccination (2 microg per dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Booster dose (5 microg) after negative conversion of anti-HBs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (responder children)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intradermal revaccinees
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intramuscular revaccinees
Number of subjects: 40
Study: 14513920

Group type: EXPERIMENTAL
Intervention: clonidine/caffeine
Number of subjects: 24

Group type: COMPARATOR
Intervention: clonidine/placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: placebo/caffeine
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo/placebo
Number of subjects: 24
Study: 11195237

Group type: EXPERIMENTAL
Intervention: Family psychosocial intervention at diagnosis
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group treated initially in a hospital ward
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Children living in one-parent families
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Children with fathers having a low level of education
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Single-parent family
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Poor glycemic control
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Maternal dysfunction
Number of subjects: 36
Study: 9212136

Group type: EXPERIMENTAL
Intervention: 3 mg epidural morphine preemptively 60 min before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3 mg epidural morphine at the conclusion of surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural placebo at the same time preoperatively
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural placebo at the end of surgery
Number of subjects: 30
Study: 7678871

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3296607

Group type: EXPERIMENTAL
Intervention: Aminophylline (5.6 mg x kg‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Thiopental (7 mg x kg‐1)
Number of subjects: 24
Study: 31531367

Group type: EXPERIMENTAL
Intervention: Closed flap technique (CFT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open flap technique (OFT)
Number of subjects: 10
Study: 28134053

Group type: EXPERIMENTAL
Intervention: r-tPA treatment
Number of subjects: 0
Study: 26013140

Group type: EXPERIMENTAL
Intervention: Local anaesthetics
Number of subjects: 45

Group type: COMPARATOR
Intervention: Anaesthetics and lavage (50 mL saline)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (Local anaesthetics and Anaesthetics and lavage)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Local anaesthetics and lavage
Number of subjects: 45
Study: 24519100

Group type: EXPERIMENTAL
Intervention: Assessment of ovarian cancer risk
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: Assessment of colon cancer risk
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: Overestimation of ovarian cancer risk
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: Underestimation of ovarian cancer risk
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: Overestimation of colon cancer risk
Number of subjects: 1555
Study: 21718959

Group type: EXPERIMENTAL
Intervention: Ulinastatin 150,000 U twice daily for 3 days
Number of subjects: 176

Group type: COMPARATOR
Intervention: Saline vehicle
Number of subjects: 176
Study: 19065051

Group type: EXPERIMENTAL
Intervention: Titration of inspired oxygen (FiO(2)) alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Adjustment to ventilator pressures with smaller changes to FiO(2)
Number of subjects: 23
Study: 17505996

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle modification program (60-hour training over 10 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 60
Study: 14656717

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (1.26 micromol.kg(‐1).min(‐1) x 6 h, n = 9)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Physiological dose of insulin (1 mU.kg(‐1).min(‐1) euglycemic hyperinsulinemic clamp x 2 h, n = 6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pharmacological dose of insulin (20 mU.kg(‐1).min(‐1) euglycemic hyperinsulinemic clamp x 2 h, n = 9)
Number of subjects: 24
Study: 11985906

Group type: EXPERIMENTAL
Intervention: Right ventricular function (measured by fractional area change [FAC])
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Right ventricular function (measured by FAC)
Number of subjects: 416
Study: 9661645

Group type: EXPERIMENTAL
Intervention: GHRH plus GHRP-6 (90 micrograms each, administered intravenously as a bolus)
Number of subjects: 26
Study: 9375232

Group type: EXPERIMENTAL
Intervention: Modified process dissociation procedure using multidimensional signal detection theory (SDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hybrid procedure preferred by Jacoby et al. (1993)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified process dissociation procedure using SDT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SDT analysis
Number of subjects: 0
Study: 2566251

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 60
Study: 56591

Group type: COMPARATOR
Intervention: Transfusion to a Hb of 10‐12 g/dl (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate hypertransfusion to a Hb of 14‐16 g/dl (group B)
Number of subjects: 30
Study: 6156614

Group type: EXPERIMENTAL
Intervention: antithymocyte globulin
Number of subjects: 41

Group type: COMPARATOR
Intervention: human leukocyte interferon
Number of subjects: 41
Study: 31758247

Group type: EXPERIMENTAL
Intervention: GI‐pill gastrointestinal electronic capsule
Number of subjects: 162

Group type: COMPARATOR
Intervention: X‐ray granule capsule
Number of subjects: 162
Study: 30261178

Group type: EXPERIMENTAL
Intervention: Wireless, hands-free audio system
Number of subjects: 960

Group type: COMPARATOR
Intervention: Standard Da Vinci Si speaker system
Number of subjects: 960
Study: 28202108

Group type: EXPERIMENTAL
Intervention: PS + budesonide
Number of subjects: 30

Group type: COMPARATOR
Intervention: PS alone
Number of subjects: 30
Study: 26024701

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 99

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 99

Group type: COMPARATOR
Intervention: Comparison of Pregabalin vs Propranolol
Number of subjects: 99
Study: 22939518

Group type: EXPERIMENTAL
Intervention: Combination of lisinopril and irbesartan (n = 70)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Lisinopril (n = 35)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Irbesartan (n = 28)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Combination of lisinopril and irbesartan
Number of subjects: 133

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 133
Study: 20652533

Group type: COMPARATOR
Intervention: Conventional technique (Group I)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Computer-assisted surgery (Group II)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Minimally invasive technique combined with computer-assisted surgery (Group III)
Number of subjects: 45
Study: 19969216

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin 0.5% drops
Number of subjects: 464

Group type: COMPARATOR
Intervention: Normal saline drops (control group)
Number of subjects: 464
Study: 17197857

Group type: EXPERIMENTAL
Intervention: Bupivacaine (3.3 mg ED95) combined with 1.5 microg sufentanil
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Ropivacaine (4.8 mg ED95) combined with 1.5 microg sufentanil
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (5.0 mg ED95) combined with 1.5 microg sufentanil
Number of subjects: 450
Study: 15593224

Group type: EXPERIMENTAL
Intervention: Treatment response
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Shorter disease duration (<=12 months)
Number of subjects: 66
Study: 12173010

Group type: EXPERIMENTAL
Intervention: CPT MBF corrected by RPP in smokers (0.65 ± 0.12 ml g(‐1) min(‐1))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPT induced increase in rate-pressure product (RPP) in smokers (10,430 ± 1,820 beats min(‐1) mmHg(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rest MBF in smokers (0.86 ± 0.11 ml g(‐1) min(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hyperaemic MBF during ATP infusion in smokers (3.20 ± 1.12 ml g(‐1) min(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Coronary flow reserve in smokers (3.78 ± 1.83)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPT MBF to resting MBF ratio
Number of subjects: 30
Study: 10213108

Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser vaporization
Number of subjects: 36

Group type: COMPARATOR
Intervention: Transurethral electroresection (TURP)
Number of subjects: 36
Study: 8553632

Group type: EXPERIMENTAL
Intervention: Zontac (histamine H2-receptor blocking agent) administered intravenously 50 mg thrice a day for 3 days, then orally 150 mg twice a day for 3 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Routine therapy (control group)
Number of subjects: 33
Study: 2146911

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 125

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 125
Study: 402459

Group type: EXPERIMENTAL
Intervention: Nasojejunal feeding (NJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nasogastric tube feeding (NG)
Number of subjects: 18
Study: 30925074

Group type: EXPERIMENTAL
Intervention: Intensive dysarthria therapy (three 40-minute sessions per week for six weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study: 31165715

Group type: EXPERIMENTAL
Intervention: 4-month online group-based nurse-led intervention
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 133
Study: 29061081

Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg)
Number of subjects: 36
Study: 26013051

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) at 85‐95% of HRmax, performed twice a week for 10 weeks on spinning bikes.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Number of subjects: 18
Study: 23163880

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 12.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipragliflozin (all doses)
Number of subjects: 0
Study: 21752511

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 0.125 mg/mL epinephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4% articaine with 0.006 mg/mL epinephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4% articaine with 0.012 mg/mL epinephrine
Number of subjects: 40
Study: 19001558

Group type: EXPERIMENTAL
Intervention: Shoes on
Number of subjects: 100

Group type: COMPARATOR
Intervention: Shoes off
Number of subjects: 100
Study: 16764623

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (n = 52)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Primary surgery (n = 54)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Stable disease (n unspecified)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Recurrent disease (n unspecified)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Partial response (n = 6)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Stable disease (n = 4)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Partial response and complete response (n = 38)
Number of subjects: 106
Study: 15385832

Group type: EXPERIMENTAL
Intervention: Everolimus starting dose of 0.75 mg bid (n = 112)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Everolimus starting dose of 1.5 mg bid (n = 125)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Cyclosporine dosing
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Everolimus C0 between 3 and 8 ng/mL
Number of subjects: 237
Study: 12386499

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrinolytics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Magnesium
Number of subjects: 0
Study: 10343660

Group type: EXPERIMENTAL
Intervention: Intervention details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control details not available
Number of subjects: 0
Study: 7658304

Group type: EXPERIMENTAL
Intervention: 0.25% itraconazole cream
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.50% itraconazole cream
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2794192

Group type: EXPERIMENTAL
Intervention: Model videotape of the principal investigator presenting a case to a parent
Number of subjects: 72

Group type: COMPARATOR
Intervention: Students evaluating their own videotaped presentation
Number of subjects: 72
Study: 326330

Group type: EXPERIMENTAL
Intervention: Triplopen
Number of subjects: 368

Group type: COMPARATOR
Intervention: Flucloxacillin
Number of subjects: 368

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 368
Study: 31412753

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1762
Study: 28657791

Group type: EXPERIMENTAL
Intervention: Heavy-load group (HLG)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Light-load group (LLG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 27
Study: 26502987

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (50-min presentation)
Number of subjects: 2173

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2173
Study: 24370959

Group type: EXPERIMENTAL
Intervention: Video exoscopy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Colposcopy
Number of subjects: 300
Study: 22352799

Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope
Number of subjects: 24

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 24
Study: 20130095

Group type: COMPARATOR
Intervention: Control (0% DHA)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: 0.32% DHA
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: 0.64% DHA
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: 0.96% DHA
Number of subjects: 343
Study: 18090696

Group type: EXPERIMENTAL
Intervention: Propofol (120.9 +/- 50.0 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Methohexital (83 +/- 26.3 mg)
Number of subjects: 50
Study: 16275379

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized hazelnut extract
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 12175374

Group type: EXPERIMENTAL
Intervention: IMZ implants
Number of subjects: 40

Group type: COMPARATOR
Intervention: ITI implants
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 10528614

Group type: EXPERIMENTAL
Intervention: pi-plate
Number of subjects: 0

Group type: COMPARATOR
Intervention: two 1/4 tube plates
Number of subjects: 0
Study: 7669314

Group type: EXPERIMENTAL
Intervention: 3% sevoflurane
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 4.5% sevoflurane
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 6% sevoflurane
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 7.5% sevoflurane
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: All concentrations
Number of subjects: 68
Study: 2200879

Group type: EXPERIMENTAL
Intervention: Mandibular cantilevered fixed partial dentures (FPDs)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Distal-extension removable partial dentures (RPDs)
Number of subjects: 53
Study: 7295615

Group type: EXPERIMENTAL
Intervention: Pindolol (1%) eye drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol (0.25%) eye drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol (0.5%) eye drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pindolol (1%) and Timolol (0.25% and 0.5%)
Number of subjects: 0
Study: 30640285

Group type: EXPERIMENTAL
Intervention: Isokinetic strength of the injured limb at RTS
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Isokinetic strength at RTS
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Comparison of isokinetic strength at RTS with preinjury strength
Number of subjects: 41
Study: 28126625

Group type: EXPERIMENTAL
Intervention: Active tDCS over left temporal lobe (T3)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 34
Study: 26782861

Group type: EXPERIMENTAL
Intervention: Intervention (algorithm-based care for depression provided by a depression care manager for 2 years)
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Intervention (algorithm-based care for depression)
Number of subjects: 1226
Study: 25161072

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat(®)
Number of subjects: 409
Study: 22383665

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI 320/9 μg or 160/9 μg
Number of subjects: 2866

Group type: EXPERIMENTAL
Intervention: budesonide pMDI 320 μg + formoterol dry powder inhaler 9 μg
Number of subjects: 2866

Group type: EXPERIMENTAL
Intervention: budesonide pMDI 320 μg
Number of subjects: 2866

Group type: EXPERIMENTAL
Intervention: formoterol dry powder inhaler 9 μg
Number of subjects: 2866

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2866
Study: 18838411

Group type: EXPERIMENTAL
Intervention: Anterior segment OCT nuclear density measurement
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Anterior segment OCT measurement
Number of subjects: 55
Study: 17218187

Group type: EXPERIMENTAL
Intervention: Information plus a brief motivational intervention (n=416)
Number of subjects: 830

Group type: COMPARATOR
Intervention: Information only (n=414)
Number of subjects: 830
Study: 15833834

Group type: EXPERIMENTAL
Intervention: Letrozole therapy for 1 month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letrozole therapy for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pretreatment sEGFR concentrations
Number of subjects: 0
Study: 12228882

Group type: EXPERIMENTAL
Intervention: Graphical method for exploring heterogeneity in meta-analyses
Number of subjects: 10850